Phosphate and CKD Bone Disease: Binders and the Mineral Axis
Phosphate is the quietest of the electrolytes — rarely on the front page of a resuscitation, easy to forget on a drug chart. Yet it sits at the centre of a web that ties together the kidney, the parathyroid glands, vitamin D and bone. Pull one thread and the whole net moves. Let it fall too low in a starving patient being fed and the muscles that breathe can fail. Let it climb in a failing kidney and, over years, the bones soften while the arteries harden. Managing phosphate is never about phosphate alone — it is about the whole mineral axis, and the drugs that hold it together are among the few you deliberately time to a meal.
A 61-year-old man with long-standing diabetic kidney disease comes to the renal clinic. He feels tired and itchy; his bones ache in a vague, deep way he cannot point to. His bloods tell the story his symptoms only hint at: phosphate high, calcium low, and a parathyroid hormone (PTH) level many times the upper limit. His arteries, on an incidental X-ray, are lined with rails of calcium. Nothing here is an emergency this afternoon — and that is exactly the danger. This is chronic kidney disease-mineral and bone disorder, assembling itself silently over years: a failing kidney that can no longer excrete phosphate or activate vitamin D, parathyroid glands screaming into the void, bones being demineralized and vessels being paved. His treatment is not one drug but a coordinated set — and the first of them is a tablet he must learn to take with every meal.
The mineral axis: four players, one balance
Phosphate never moves in isolation — it moves with calcium, PTH and vitamin D. Most of the body's phosphate is locked in bone as calcium phosphate; the small fraction in the blood is what we measure. Four regulators hold the balance. Vitamin D, once activated, raises both calcium and phosphate by boosting their absorption from the gut. PTH, released when calcium falls, pulls calcium out of bone, tells the kidney to hold calcium but dump phosphate, and switches on the kidney enzyme that activates vitamin D. The kidney is the pivot: it performs the final activation step of vitamin D (1-alpha-hydroxylation) and it is the main exit route for phosphate. Grasp that geometry and every disorder in this article becomes predictable — the mechanisms of PTH, vitamin D activation and calcium handling are developed further in the Endocrine section.
Hypophosphataemia: the shift is the killer
Low phosphate has three broad routes in, but one dominates the wards: a sudden shift into cells. The most dangerous cause is not loss from the body at all, but a transcellular shift — phosphate rushing out of the blood and into cells. The classic trigger is refeeding syndrome: feed a starved patient carbohydrate and the resulting surge of insulin drives phosphate (along with potassium and magnesium) into cells to build ATP and phosphorylated intermediates, stripping the serum in hours. The same insulin-driven shift is why phosphate falls during treatment of diabetic ketoacidosis (DKA), and respiratory alkalosis (hyperventilation) does it too by pushing phosphate into cells. This is the deadly heart of refeeding syndrome — covered in full in the Refeeding syndrome chapter — and the reason you check and replace phosphate before and during feeding, not after the patient collapses.
The other two routes matter but act more slowly. Renal loss — the kidney failing to reclaim phosphate — occurs in primary hyperparathyroidism (high PTH is phosphaturic), in Fanconi syndrome (a leaky proximal tubule), with certain drugs, and, importantly, after intravenous iron: some modern IV iron preparations cause a genuine, sometimes marked and prolonged hypophosphataemia by inducing the phosphate-wasting hormone FGF23 — a link back to the Haematology iron chapter and one clinicians increasingly watch for. The third route is gut loss and poor intake: malnutrition, chronic alcohol use, malabsorption, and prolonged use of phosphate-binding antacids that trap dietary phosphate in the gut. Most low-phosphate states are a blend — the alcoholic being refed is losing on every front at once.
Think of serum phosphate like the cash in a shop's till. A low till doesn't always mean the business is broke — sometimes the money has just been swept into the safe (the cells) all at once. That is the refeeding shift: the total isn't gone, it has moved somewhere you can't spend it from. Refill the till too casually with calcium-containing phosphate and you risk the two salts clumping into an insoluble deposit — like trying to cram wet cement back through the slot. It has to go in slowly, and you keep an eye on the calcium while you do it.
When phosphate falls too far: the body runs out of ATP
Mild hypophosphataemia is often silent. Severe hypophosphataemia is dangerous precisely because phosphate is the backbone of ATP — the cell's energy currency — and of 2,3-DPG in red cells. Starve tissues of phosphate and energy-hungry cells fail. Skeletal muscle weakens; when the diaphragm and respiratory muscles are involved a patient may fail to wean from a ventilator, and the heart muscle can weaken too. The membrane fragility can trigger rhabdomyolysis (muscle breakdown) and haemolysis (red-cell rupture). The brain, running on a failing energy supply, produces confusion, irritability and, at the extreme, seizures. The lesson is that a number on a chart which looks like a minor derangement can, when severe, translate into a patient who cannot breathe or think.
Replacement is graded by severity — and the risk sits in the fast route. Mild-to-moderate hypophosphataemia is treated with oral phosphate supplements (often as effervescent phosphate salts), the safe and preferred route. Severe or symptomatic hypophosphataemia needs intravenous phosphate, given slowly and cautiously — infused too fast it can precipitate with serum calcium (that insoluble clumping) and pull the calcium down, sometimes sharply. So you replace over hours, not minutes, and you monitor calcium alongside phosphate. In the refed and the alcoholic, remember that low magnesium travels with low phosphate and must be corrected too, or the phosphate (and potassium) will not stay corrected.
The most useful reflex in phosphate medicine is to ask "where has it gone?" before "how much do I give?" A shifted phosphate (refeeding, DKA insulin, alkalosis) and a depleted phosphate (chronic loss) look identical on the lab report but behave differently: the shift can plummet fast and rebound as insulin wanes, so you anticipate and pre-empt it rather than chase it. This is why refeeding protocols start feeding low and slow, give thiamine, and check phosphate, potassium and magnesium daily — you are defusing a shift before it happens.
- Phosphate, calcium, PTH and vitamin D form one interlocking axis pivoting on the kidney.
- The dominant cause of acute hypophosphataemia is a transcellular shift — refeeding, insulin/DKA treatment, respiratory alkalosis.
- Other causes: renal loss (hyperparathyroidism, Fanconi, drugs, IV iron via FGF23) and GI loss / poor intake / phosphate-binding antacids.
- Severe hypophosphataemia depletes ATP: muscle weakness (respiratory, cardiac), rhabdomyolysis, haemolysis, confusion.
- Oral phosphate for mild; IV phosphate for severe — slowly, watching calcium (it can precipitate and drop calcium).
- Correct magnesium alongside — low Mg2+ perpetuates low phosphate and potassium.
Hyperphosphataemia: mostly a kidney problem
High phosphate has a much shorter differential, because the kidney is so good at excreting it that levels only climb when the kidney fails or when phosphate is dumped into the blood faster than even healthy kidneys can clear it. The overwhelmingly commonest cause is chronic kidney disease: as functioning nephrons are lost, phosphate excretion falls and phosphate accumulates. The second group is massive cell breakdown, which spills intracellular phosphate into the blood — tumour lysis syndrome (covered in the Oncology emergencies chapter) and rhabdomyolysis (in the Toxicology section). The third is excess intake or absorption — most notoriously phosphate-containing bowel-preparation solutions and phosphate enemas, which can cause a dangerous acute rise, especially in older patients or those with reduced renal function.
CKD-MBD: the story that ties it all together
This is the single most important integrating concept — read the cascade one step at a time. As the kidney fails, two things happen at once. First, it can no longer excrete phosphate, so phosphate is retained. Second, it can no longer complete the activation of vitamin D (the failing 1-alpha-hydroxylation step), so active vitamin D falls. Low active vitamin D means less calcium is absorbed from the gut, and retained phosphate binds calcium in the blood — both push calcium down. Low calcium (helped along by the loss of vitamin D's direct suppression) drives the parathyroid glands to pump out ever more PTH: secondary hyperparathyroidism. Chronically high PTH strips mineral from bone, producing renal osteodystrophy — soft, painful, fracture-prone bone — while the high phosphate-calcium product drives deposition of calcium into blood vessels and soft tissue: vascular calcification, the reason CKD patients die of cardiovascular disease more than anything else. The CKD and active-vitamin-D themes recur in the Nephrotoxic drugs / renal and Hypocalcaemia chapters.
The drugs map onto the cascade, step by step
Because CKD-MBD is a chain, the treatment is a set of drugs each aimed at one link. Step one, tackle the retained phosphate with phosphate binders — tablets taken with meals that bind dietary phosphate in the gut so it is passed in the stool rather than absorbed. Their timing is the whole point: a binder swallowed away from food binds nothing. Calcium-based binders (calcium carbonate, calcium acetate) are cheap and effective but add a calcium load that can worsen vascular calcification, so they are used with a ceiling. Non-calcium binders avoid that load and are often preferred: sevelamer and lanthanum carbonate, and the iron-based binders ferric citrate and sucroferric oxyhydroxide (which can nudge iron stores up as a bonus). Step two, replace the active vitamin D the kidney can no longer make with active vitamin D analogues — alfacalcidol, calcitriol or paricalcitol — which bypass the failed renal hydroxylation to raise calcium and directly suppress PTH. Step three, if PTH stays high, add a calcimimetic — oral cinacalcet or intravenous etelcalcetide — which makes the parathyroid's calcium-sensing receptor more sensitive to calcium, so the gland "thinks" calcium is higher and lowers PTH directly. Underpinning all three is dietary phosphate restriction.
Phosphate binders are one of the very few drugs whose timing relative to food is the entire mechanism. A binder works only where it can meet the phosphate in a meal, so it must be chewed or swallowed with the first mouthfuls — not on an empty stomach, not an hour later. Patients who take their "phosphate tablets" dutifully but at bedtime with everything else get no benefit and a rising phosphate that looks like non-adherence. Counselling on timing is as important as the prescription itself.
Phosphate binders (with meals): calcium carbonate, calcium acetate (calcium-based, cheap, watch calcium load); sevelamer, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide (non-calcium, preferred to limit calcium load). Active vitamin D analogues (suppress PTH, raise calcium): alfacalcidol, calcitriol, paricalcitol. Calcimimetics (lower PTH directly for secondary hyperparathyroidism): cinacalcet (oral), etelcalcetide (IV, given at dialysis). Plus dietary phosphate restriction. In hyperphosphataemia from tumour lysis or bowel-prep, the answer is different — treat the underlying cause and support the kidney; binders are a chronic-CKD tool, not an acute fix.
- Hyperphosphataemia is mainly CKD (reduced excretion); also cell breakdown (tumour lysis, rhabdomyolysis) and excess intake (enemas/bowel prep).
- CKD-MBD: phosphate retention + low active vitamin D → low calcium → secondary hyperparathyroidism → renal osteodystrophy + vascular calcification.
- Phosphate binders bind dietary phosphate in the gut and MUST be taken with meals.
- Non-calcium binders (sevelamer, lanthanum, iron-based) are often preferred over calcium-based ones to limit calcium/vascular-calcification load.
- Active vitamin D analogues (alfacalcidol, calcitriol, paricalcitol) bypass the failed kidney to suppress PTH and support calcium.
- Calcimimetics (cinacalcet, etelcalcetide) lower PTH directly via the calcium-sensing receptor.
- Prescribing phosphate binders without teaching the timing — taken away from meals they bind nothing, and the phosphate keeps climbing.
- Missing the refeeding shift — feeding a starved or alcoholic patient without checking and replacing phosphate (and giving thiamine first) can be fatal.
- Loading a CKD patient with calcium-based binders and active vitamin D without watching calcium — you can drive hypercalcaemia and worsen vascular calcification.
A 58-year-old man on haemodialysis has a persistently high serum phosphate despite dietary advice. He takes calcium carbonate but reports swallowing all his tablets together at bedtime. Which single change is most likely to lower his phosphate?
- Phosphate is regulated with calcium, PTH and vitamin D on an axis pivoting on the kidney — never manage it alone.
- Hypophosphataemia: the dangerous cause is a transcellular shift (refeeding, insulin/DKA, alkalosis); severe cases fail muscle (respiratory/cardiac), cause rhabdomyolysis/haemolysis and confusion. Oral for mild, cautious IV for severe.
- Hyperphosphataemia is mainly CKD, plus cell breakdown (tumour lysis, rhabdomyolysis) and excess intake (enemas/bowel prep).
- CKD-MBD is managed as a cascade: meal-timed phosphate binders (non-calcium preferred), active vitamin D analogues, calcimimetics and dietary restriction — treating phosphate, calcium, vitamin D and PTH together.
- Rang & Dale's Pharmacology — bone mineral homeostasis: calcium, phosphate, PTH and vitamin D.
- Katzung Basic & Clinical Pharmacology — agents that affect bone mineral homeostasis; phosphate binders and calcimimetics.
- British National Formulary (BNF) — phosphate binders (sevelamer, lanthanum, calcium salts, ferric citrate, sucroferric oxyhydroxide), alfacalcidol/calcitriol/paricalcitol, cinacalcet, etelcalcetide.
- NICE guideline — Chronic kidney disease: assessment and management; and hyperphosphataemia in CKD (management of the mineral-bone disorder).
- KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
- NICE guideline CG32 — Nutrition support in adults (refeeding syndrome and phosphate replacement); Ganong/Guyton physiology for the phosphate–ATP basis.
